Addex spin-out Neurosterix completes Phase 1 studies of NTX-253 for schizophrenia
ADXN•Neurosterix, an Addex Therapeutics spin-out, completed Phase 1 clinical studies of NTX-253 for schizophrenia and plans Phase 2 development.
1. Study completion
Neurosterix completed Phase 1 clinical studies of NTX-253 for schizophrenia. Addex Therapeutics said Neurosterix plans Phase 2 development.
